Royalty Pharma plc (RPRX) Earnings

Royalty Pharma plc

RPRX · Nasdaq

Sep 2026upcoming

Next quarter

Reports Nov 4, 2026.

Consensus is $1.18 EPS for Sep 2026 across 4 estimates, ranging $1.14 to $1.21.

RPRX Jun 2026

Reported Aug 5, 2026 · before the open

: 3.94%

: $1.27
: $1.32
: —
: $674.14M

Reported results

: $674.14M; from $578.66M
: $133.12M; from $209.80M
: 19.75%; from 36.26%
: $17.88M; from $32.18M
: $0.04; from $0.07

Highlights

Revenue was $0.67 billion, compared with $0.58 billion in the second quarter of 2025 and $0.63 billion in the first quarter of 2026.
Net income was $0.02 billion, versus $0.03 billion in the year-ago quarter and $0.29 billion in the prior quarter.
Royalty Pharma operates as one reportable segment focused primarily on acquiring biopharmaceutical royalties; the filing provides no separate segment revenue or profit figures.
Total share-based compensation was $107.356 million, up from $91.044 million in the second quarter of 2025, including $73.503 million for Employee EPAs and $31.922 million for RP Holdings Class E Interests.
Total EPAs earned were $16.729 million in the quarter and $50.247 million for the first six months, compared with $2.031 million and $43.508 million, respectively, in the comparable 2025 periods.
The company repurchased 2.0 million shares for approximately $95.6 million in the first six months, with approximately $1.7 billion remaining under the program; Cytokinetics funding commitments of up to $175 million were available through the fourth quarter of 2026.

Symbol: RPRX
Type: Stock
Sector: Health Care
Industry: Pharmaceutical Preparations
Exchange: Nasdaq

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators.

Key Issues

Bullish view

Adjusted EBITDA increased to $736 million from $633 million, while quarterly earnings and revenue exceeded estimates by 3.94% and 1.52%. That supports a view that underlying operating performance remains strong despite lower reported net income.

Bearish view

Net income attributable to Royalty Pharma declined to $18 million from $32 million. Investors may therefore question whether the stronger adjusted EBITDA meaningfully translates into bottom-line earnings.

Analyst Consensus

See all

Buy

7 analysts

$60

Current

—

Low

$66

Average

—

High

Average target implies +10.78% versus the current price.

Earnings History

BeatMissNo estimate

Royalty Pharma plc

Next quarter

Reported results

Highlights

Peers